Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets

Inorganica Chimica Acta

Volumn 393, Issue , 2012, Pages 173-181

  Moghaddas, Shadi ^a   Majmudar, Pooja ^a,b   Marin, Roberto ^a,c   Dezvareh, Homa ^a   Qi, Chunyan ^a,d   Soans, Eroica ^a,e   Bose, Rathindra N ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^d Ohio University   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

in vitro efficacy of phosphaplatins; In vivo efficacy of phosphaplatins; Maximum tolerated dose of phosphaplatins; Non DNA binding platinum anticancer agents; Protein binding of phosphaplatins; Reduced toxicity of phosphaplatins

Indexed keywords

AMINES; BIOCHEMISTRY; BLOOD; CELL DEATH; COMPLEXATION; DISEASES; DNA; DRUG PRODUCTS; LEAD COMPOUNDS; MAMMALS; PROTEINS; STEREOCHEMISTRY;

ANTI-CANCER AGENTS; IN-VITRO; IN-VIVO; MAXIMUM TOLERATED DOSE; PROTEIN BINDING; REDUCED TOXICITY;

PLATINUM COMPOUNDS;

EID: 84868555575     PISSN: 00201693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ica.2012.05.040     Document Type: Article

References (35)

1. L. Kelland Nat. Rev. 7 2007 574
2. N.J. Wheate, S. Walker, G.E. Craig, and R. Oun Dalton Trans. 39 2010 8113
3. L.M. Pasetto, M.R. D'Andrea, A.A. Brandes, E. Rossi, and S. Monfardini Crit. Rev. Oncol. Hematol. 60 2006 59
4. G.D. Girnun, L. Chen, J. Silvaggi, R. Drapkin, and L.R. Chirieac Clin. Cancer Res. 14 2008 6478 6486
5. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, and T. Hayashi Br. J. Cancer 93 2005 678
6. V.A. Carozzi, P. Marmiroli, and G. Cavaletti Curr. Cancer Drug Targets 10 2010 670
7. D. Wang, and S.J. Lippard Nat. Rev. Drug Discov. 4 2005 307 320
8. Z.H. Siddik Oncogene 22 2003 7265 7279
9. M. Marinez-Rivera, and Z.H. Siddik Biochem. Phramcol. 83 2012 1049 1062
10. R.P. Wernyj, and P.J. Morin Drug Resist. Updat. 7 2004 227
11. W. Lee PLoS Genet. 1 2 2005 e24
12. W. Sakai, E.M. Swisher, B.Y. Karlan, M.K. Agarwal, and J. Higgins Nature 451 2008 1116
13. A. Brozovic, and M. Osmak Cancer Lett. 25 2007 1 16
14. A.K. Godwin Proc. Natl. Acad. Sci. USA 89 1992 3070
15. H. Yang, B. Higgins, K. Kolinsky, K. Packman, and W.D. Bradley Cancer Res. 72 2012 779
16. R.J. Mishur, C. Zheng, T.M. Gilbert, and R.N. Bose Inorg. Chem. 47 2008 7972
17. R.N. Bose, L. Maurmann, R.J. Mishur, L. Yasui, and S. Gupta Proc Natl. Acad. Sci. USA 105 2008 18314
18. R.N. Bose, Phosphaplatins and their treatment to cancer resistant to cisplatin and carboplatin, Patent No. US 7,700,649, 2010
19. R.N. Bose, Patent No. US 8,034,964 B2 (2011).
20. Bose, R.N., Phosphaplatins and their uses for treatment of cancers, Application No. PCT/US2011/38948, 2011.
21. Bose, R.N., Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and their uses thereof, Application No. PCT/US2011/063139, 2011.
22. P. Majmudar, Investigating Molecular Targets of Phosphaplatins: A Class of Novel Non-DNA-Binding Platinum Anticancer Agents in the Treatment of Ovarian Cancer, Ph.D. dissertation, Ohio University, 2011.
23. R.N. Bose, R.E. Viola, and R.D. Cornelius J. Am. Chem. Soc. 106 1984 3336
24. R.N. Bose, R.D. Cornelius, and R.E. Viola Inorg. Chem. 24 1985 3989
25. M. Liu, R.W. Bishop, Y. Wang, Kirschmeier, Transgenic vs. Xenograft Mouse Mode of Cancer, Molecular Cancer Therapeutics, Prendergast, Ed., Wiley, 2004, pp. 205-222.
26. M.C. Alley, M.G. Hollingshead, D.J. Dykes, W.R. Wand, Human Tumor Xenograft Model in NCI Drug Development, in: B.A. Teicher, P.A. Andrews, Anticancer Drug Development Guide, Humana Press, New Jersey, 2004, pp. 137-140.
27. Hong et al., Cancer Res. 70 (2010) 5518-5526.
28. P. Devarajan, R. Tarabishi, J.M.A. Qing, A. Kourvetaris, M. Vougiouka, and T. Boulikas Anticancer Res. 24 2004 2193 2200
29. L.P. Dudones, and R.N. Bose Pharmaceut. Res. 19 2002 124
30. A. Eastman Biochem. Pharmacol. 36 1987 4177 4178
31. M. Komatsu, T. Sumizawa, M. Mutoh, Z.S. Chen, and K. Terada Cancer Res. 60 2000 1312
32. D.J. Stewart Crit. Rev. Oncol. Hematol. 63 2007 12
33. A. Eastman Cancer Cells 2 1990 275
34. C.M. Sorenson, and A. Eastman Cancer Res. 48 1988 4484
35. W. Lee, R.P. St Onge, M. Proctor, P. Flaherty, M.I. Jordan, et al., PLoS Genet. 1 (1995) e24.